Accelerate Specialty Network

The first and largest specialty PSAO in the market

Start a conversation

100+

accredited specialty pharmacies in the network

75%

of pharmacies have EMR access - clinically integrated model

330,000+

physicians/providers connected/affiliated to the participating pharmacy locations/IDNs

More than

550

affiliated hospital/clinic locations tied to these IDNs

Accelerate Specialty Network truly focuses on collaboration

Customizable solutions for payers to fit their current strategy

We partner with payers to reimagine the future of care delivery and managed care models. Together, we break down barriers to care, help enable streamlined treatment pathways, and make meaningful strides toward reducing the total cost care for all stakeholders.

Supporting a unique network of clinically-integrated and strategic independent specialty pharmacies

Health systems and IDNs

Industry leading health systems and IDNs with comprehensive specialty pharmacy capabilities

Medically Integrated Dispensing (MID) practices

Large specialty physician practices with in-office dispensing capabilities

Strategic independent specialty pharmacies

Patient-centric specialty pharmacies with no payer or extra organizational ownership

The most expansive pharmacy network in a specialty PSAO

Accelerate Specialty Network pharmacies have multi-state licensure that provides overlapping dispensing coverage in nearly every U.S. state and territory.

Accessible prescriptions, no matter where the patient lives

Accelerate Specialty Network encompasses leading clinically integrated, and accredited specialty pharmacies from across the country.

A comprehensive and growing footprint of clinically integrated sites of care

Accelerate Specialty Network is the only specialty PSAO that:

Has an established network of specialty pharmacies, with comprehensive coverage and access to LDDs
Has a robust pipeline of new specialty pharmacies that will expand access to patients across the country
Actively participates in specialty contracts with national health plans and PBMs, and understands the requirements and nuances for contracting
Is focused on partnerships and how we can collectively, not competitively, move health forward

Has robust data capabilities that promote transparency into business operations
Is backed by an organization focused on innovation and continued investment in infrastructure and transformative healthcare solutions
Offers expanded touch-points for patient to access prescriptions in a way that’s most convenient

The benefits of Accelerate Specialty Network

Health system and MID practices

Access to the patient’s EMR for real-time decision making
Integration with the patient’s care team
On-site dispensing for improved speed to therapy

Local pharmacies

Flexible prescription options for patients within their communities or via mail
Promotes in-person pharmacist relationships where monitoring can occur
Provides 50-state coverage in most instances

Improved health outcomes

Clinically integrated care informed by the patient’s EMR helps enable improved therapy management and clinical oversight

Reduction in total cost of care

Real-time data helps providers work agilely in managing the patient’s therapeutic journey, including reducing waste

Improved member experience

Accessible community-based care and deep provider integration empowers patients to get on therapy faster with less interruption through an integrated care model

Increased administrative efficiency

Our powerful tools and resources as a PSAO help reduce administrative complexities and streamline the contracting and reimbursement processes

Resources

Peer-reviewed journal article:

Health System Specialty Pharmacies Decrease Total Cost of Care in Cancer Treatment, a Multisite Review

Integrated delivery networks can use medically integrated dispensing of oral oncolytics on site through health system specialty pharmacies. There is little published research examining cost savings. Our objective was to demonstrate the financial value of health system specialty pharmacies among patients receiving oral oncolytics dispensed through fully, partially, and non-integrated dispensing strategies.

In this study, we discovered that IDNs and their HSSPs generated a significant impact to the total cost of cancer care:

38% savings on oral oncolytic prescriptions during the DoT
32% savings on medical care in a 6-month follow up
14% savings on oral oncolytic prescriptions in a 6-month follow up

Read the article